Macrocyclic HDM2 Inhibitors for p53 Reactivation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for effective inhibitors of the HDM2 or MDM2 protein to treat or prevent cancer and other diseases associated with cell proliferation, as current methods are inadequate in addressing the interaction between HDM2 and p53, leading to uncontrolled cell growth and tumor formation.
Innovation Solution
Development of novel macrocyclic compounds that act as HDM2 or MDM2 antagonists, which inhibit the interaction between HDM2 and p53, thereby activating p53 and regulating cell proliferation, are introduced. These compounds are designed to be used in pharmaceutical compositions for treating diseases associated with HDM2, MDM2, or p53.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If HDM2 protein is allowed to interact with p53, then cell cycle regulation and apoptosis are maintained, but tumor proliferation and uncontrolled cell growth occur
Solution Approach 1:
The patent introduces HDM2 inhibitor compounds as intermediary substances that bind to HDM2 protein, preventing its interaction with p53. These compounds act as mediators that block the harmful interaction between HDM2 and p53, thereby maintaining p53 activity and preventing tumor proliferation without directly affecting either protein's normal function.
Solution Approach 2:
The patent extracts or removes the harmful interaction between HDM2 and p53 by using inhibitor compounds that specifically target and block this interaction. The inhibitors separate the functional roles of HDM2 and p53, allowing p53 to maintain its tumor suppressor activity while HDM2's oncogenic effect is neutralized.
2Productivity
If HDM2 protein levels are increased, then cell proliferation is promoted, but p53 activity is down-regulated leading to loss of cell cycle control
Solution Approach 1:
The HDM2 inhibitor compounds serve as intermediaries that bind to HDM2 protein, preventing it from down-regulating p53 activity. These inhibitors allow high levels of HDM2 to be present without the harmful effect of p53 suppression, thereby maintaining cell cycle control while permitting cell proliferation.
Solution Approach 2:
The patent extracts the harmful downstream effect of HDM2 excess by using inhibitors that specifically block HDM2's ability to interact with and suppress p53. This allows the system to tolerate high HDM2 levels without losing p53-mediated cell cycle regulation.
3Reliability
If p53 activity is increased, then apoptosis and cell cycle arrest are enhanced, but normal cell function and survival are compromised
Solution Approach 1:
The HDM2 inhibitors act as protective intermediaries that allow p53 to maintain its activity without causing excessive cellular stress. By blocking HDM2's interaction with p53, the inhibitors prevent the feedback loop that would otherwise lead to runaway p53 activation and cell death, thereby enabling controlled p53 function.
Solution Approach 2:
The patent extracts the feedback mechanism that causes harmful cellular stress by using inhibitors to block HDM2-p53 interaction. This removes the negative feedback loop, allowing p53 to function without triggering the stress responses that would normally occur at excessive p53 levels.
Data Source
AI summary
The present invention provides a compound of Formula (1): as described herein or a pharmaceutically acceptable salt or solvate thereof. The compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same.